A novel disease-preventing antioxidant pathway

May 27, 2014

Interested in antioxidants? They protect us against aging and cancer. It's one of the reasons we like our green tea and even our broccoli. But there is a new kid on the antioxidant block - uric acid. But wait, you're thinking, doesn't uric acid cause gout? A team in Singapore has recently showed that uric acid is a major intracellular antioxidant, possibly even more important than the antioxidants we try to eat. They also discovered how uric acid helps to prevent aging and disease and how it helps in the treatment of cancer.

Traditionally, has a bad reputation because high levels of the compound are associated with gout and other medical conditions. However, uric acid also has antioxidant properties. Since only humans and higher primates maintain high blood levels of uric acid near saturated levels, uric acid has been speculated to be one reason humans live so much longer than, for example, dogs and cats.

This recently released study, led by Assistant Professor Koji Itahana of Duke-NUS Graduate Medical School Singapore, has also discovered how uric acid gets into cells to protect them in the event of stress. It goes through a transporter GLUT9 and is regulated by the protein p53, one of the most important tumor suppressors that mutated in about a half of cancers worldwide.

The team from the Cancer and Stem Cell Biology Program at Duke-NUS showed first evidence of how the p53-GLUT9 pathway is a mechanism that prevents the accumulation of Reactive oxygen species (ROS). ROS are molecules containing highly reactive oxygen and at times of environmental stress can increase dramatically, and result in cell damage known as . Oxidative stress has been proven to cause aging, cancer, cardiovascular and neurodegenerative diseases.

Understanding this antioxidant pathway will enable researchers and clinicians to better understand how to prevent aging and other such diseases. Interestingly, Dr. Itahana also showed that shutting down the GLUT9 antioxidant pathway in cancer may be an unorthodox way to target cancer once the patient already has the disease.

"While the p53-GLUT9 mechanism is a way that helps prevent disease in a healthy body, once the body already has cancer, disrupting that same mechanism may be a way to kill the cancer since cancer has already very high levels of ROS. For instance if a patient were to take probenecid, a gout drug that inhibits the function of GLUT9 and a chemo drug, ROS levels would become so high that cells may not be able to survive in the body because there is simply no space," explained Dr. Itahana.

The study is published on May 26, 2014 in the journal Oncogene.

Explore further: Adding uric acid to standard stroke clot busters reduces stroke disability

Related Stories

Adding uric acid to standard stroke clot busters reduces stroke disability

February 13, 2014
Giving stroke patients uric acid along with standard clot-busting medication within 4.5 hours of first symptoms appears safe and effective at limiting disability, according to late-breaking science presented at the American ...

Does high uric acid predispose diabetic patients to kidney disease?

January 15, 2014
Kidney disease poses one of the greatest burdens for people living with type 1 diabetes. A study newly awarded by the National Institutes of Health (NIH) will look at whether lowering uric acid levels can prevent people with ...

A braking system for immune responses: Researchers find receptor for uric acid crystals

March 20, 2014
For the first time, researchers have identified a receptor on human cells that specifically recognizes crystals. It is found on immune cells and binds uric acid crystals, which trigger gout but also control immune responses. ...

Vitamin C does not lower uric acid levels in gout patients

May 16, 2013
Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients ...

Scarcity of fruit millions of years ago could have caused loss of enzyme that prevents gout

February 18, 2014
(Medical Xpress)—Apes, including humans, lack an enzyme called uricase that breaks down uric acid. Because we lack uricase, we are predisposed to developing gout. After reconstructing ancient versions of the enzyme found ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.